Key Indicators of Value & Success in a Life Science Company: What Investors Look For
30 September 2009
Venture Capital and strategic investors value new and emerging life science companies differently in these challenging times. Entrepreneurs have been forced to modify business plans to stay afloat, while investors have taken a different approach to determining a life science company’s value.
This session will cover long-term strategies that emerging life science businesses should consider when seeking investors, while highlighting opportunities for investors in discovering and creating sustainable value.
-
Diverse perspectives from angel investors to mid-tier funds
-
Issues and perspective from the entrepreneur’s view
-
State of the venture and strategic markets and current trends
-
Factors to be considered in determining the investment opportunities and future returns of life science companies
-
The role of IP in value creation
-
Understanding market opportunities and constraints
Panelists:
-
Gabor Garai, Partner, Foley & Lardner LLP
-
Patrick Heron, General Partner, Frazier Healthcare Ventures
-
Jay S. Kunin, Ph.D., Vice President, TechCoast Angels
-
Bill Molloie, Partner, San Diego Life Sciences Lead, Pricewaterhouse Coopers
-
Hans Petersen, CEO, Traversa Therapeutics
Related Insights
21 March 2025
IP Litigation Current
Federal Circuit Opens the Door to Additional Domestic Industry Investment: “Ordinary Importer” No Longer
In its recent decision in Lashify, Inc. v. International Trade Commission, the Federal Circuit opened the door for patent owners to include expanded categories of domestic investment to satisfy the economic prong of the domestic industry requirement under Section 337(a)(3)(B).
21 March 2025
Manufacturing Industry Advisor
Federal Court Rejects FCA’s “65%-100%” Language as Insufficient to Constitute the Necessary Quantity Term in a Requirements Contract—A Win for Suppliers
A recent federal court decision marks an important win for automotive suppliers in the ongoing debate over what constitutes a valid requirements contract under Michigan law following the Michigan Supreme Court’s decision in MSSN, Inc. v. Airboss Flexible Products Co. (2023).
27 April 2025
Events
Innovative Payment Strategies in Proton Therapy: Addressing Challenges and Driving Value
Foley partner Kinal Patel is speaking at the 2025 National Proton Conference in a panel titled “Innovative Payment Strategies in Proton Therapy: Addressing Challenges and Driving Value” on April 27.